RxDoctor Payments DataLook up a doctor →

Stanley Chetcuti, MD

Cardiovascular Disease · Ann Arbor, MINPI 1467503516

Payments from drug & device makers

$4,321,503in general payments, 2019–2025

Across 2,187 payments — averaging $1976.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2.3M
  • Edwards Lifesciences$881K
  • Boston Scientific$514K
  • W. L. Gore & Associates, Inc.$181K
  • Jenavalve Technology, Inc.$152K
  • Abbott$136K
  • plus $122K from 11 others
$64,850in research payments, 2019–2025

Across 41 payments — averaging $1581.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$65K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,321,503 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$114,821
Medicare patients
258
Services billed
534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →